Leman Biotech has recently received extensive evaluations from renowned institutions and companies in the Guangdong, Hong Kong, Macao, and Greater Bay Area. Notable entities such as Guangdong Hengjian Investment Holdings Limited, Hong Kong Cyberport, top PE BPEA EQT, Zhuhai Zhengling Venture Capital, Zhuhai Zhengfang Group, and Xiangxue Pharmaceutical have assessed Leman Biotech's core technology, R&D progress, talent team, and development plans.
.jpg)
During the evaluation process, Leman Biotech's co-founder, Dr. Yugang Guo, R&D director Dr. Dudu Tong, and Dr. Li Youjia, along with other representatives from the R&D team, engaged in in-depth discussions with the representatives of each institution or enterprise. Dr. Guo Yugang highlighted the unique advantages of Leman Biotech's core technologies, shared the latest advancements in each pipeline and clinical trials, and provided insights into the company's team building, collaboration models, financing, and potential future cooperation plans.
Headquarted in the Shenzhen International Biomedical Industrial Park and in Biopole, Lausanne Switzerland, Leman Biotech has made remarkable progress in the past year. The company has initiated two IIT clinical studies on novel cell therapy (NCT05715606, NCT05747157). This intensive evaluation from prominent institutions and enterprises further demonstrates Leman Biotech's growing presence and potential in the industry.
